Drugs / ETRINABDIONE
ETRINABDIONE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03745001 | Sep 2018 → Aug 2019 | — | Emerald Health Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04909502 | Oct 2021 → Dec 2023 | multiple sclerosis | Emerald Health Pharmaceuticals | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04166552 | Jun 2020 → Jul 2024 | diffuse cutaneous systemic sclerosis | Emerald Health Pharmaceuticals | Suspended | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETRINABDIONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095098 ↗ |
| Known as | EHP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03745001 ↗ |
| Known as | Etrinabdiona | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095098 ↗ |
| Known as | VCE-004 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095098 ↗ |
| Known as | VCE-004.8 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095098 ↗ |
| Modality | Small molecule | — CHEMBL5095098 ↗ |
| Route | Oral | “One single oral administration with EHP-101 liquid formulation.” NCT03745001 ↗ |